CRSP
Price
$50.41
Change
-$0.05 (-0.10%)
Updated
Jul 15, 11:52 AM (EDT)
Capitalization
4.97B
26 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$3.16
Change
-$0.00 (-0.00%)
Updated
Jul 14 closing price
Capitalization
484.94M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRSP vs EDIT

CRSP vs EDIT Comparison Chart in %
View a ticker or compare two or three
VS
CRSP vs. EDIT commentary
Jul 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and EDIT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2026
Stock price -- (CRSP: $50.46 vs. EDIT: $3.16)
Brand notoriety: CRSP and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 60% vs. EDIT: 38%
Market capitalization -- CRSP: $4.97B vs. EDIT: $484.94M
CRSP [@Biotechnology] is valued at $4.97B. EDIT’s [@Biotechnology] market capitalization is $484.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $120.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 6 bearish.
  • EDIT’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than EDIT.

Price Growth

CRSP (@Biotechnology) experienced а -16.97% price change this week, while EDIT (@Biotechnology) price change was -15.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.56%. For the same industry, the average monthly price growth was +6.71%, and the average quarterly price growth was +1866.59%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 10, 2026.

EDIT is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Biotechnology (-3.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.97B) has a higher market cap than EDIT($485M). EDIT YTD gains are higher at: 54.146 vs. CRSP (-3.776). EDIT has higher annual earnings (EBITDA): -100.08M vs. CRSP (-627.33M). CRSP has more cash in the bank: 2.44B vs. EDIT (124M). EDIT has less debt than CRSP: EDIT (17.3M) vs CRSP (788M). EDIT has higher revenues than CRSP: EDIT (38.7M) vs CRSP (1M).
CRSPEDITCRSP / EDIT
Capitalization4.97B485M1,025%
EBITDA-627.33M-100.08M627%
Gain YTD-3.77654.146-7%
P/E RatioN/AN/A-
Revenue1M38.7M3%
Total Cash2.44B124M1,969%
Total Debt788M17.3M4,555%
FUNDAMENTALS RATINGS
CRSP vs EDIT: Fundamental Ratings
CRSP
EDIT
OUTLOOK RATING
1..100
7631
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6040
P/E GROWTH RATING
1..100
74100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (87) in the Biotechnology industry is in the same range as CRSP (91). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (98) in the Biotechnology industry is in the same range as EDIT (100). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (40) in the Biotechnology industry is in the same range as CRSP (60). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (74) in the Biotechnology industry is in the same range as EDIT (100). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPEDIT
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 14 days ago
79%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PGF13.70N/A
+0.01%
Invesco Financial Preferred ETF
IEI116.77N/A
N/A
iShares 3-7 Year Treasury Bond ETF
EVMT17.61N/A
N/A
Invesco Elctc vhcl Mtls Cmd StgyNoK-1ETF
MFVL20.63N/A
N/A
Motley Fool Value Factor ETF
GDXD49.46-3.65
-6.87%
MicroSectors™ Gold Mns 3X Inv Lvrgd ETN

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRBU. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
N/A
CRBU - EDIT
65%
Loosely correlated
-2.78%
BEAM - EDIT
63%
Loosely correlated
-0.35%
PRME - EDIT
61%
Loosely correlated
-1.28%
CRSP - EDIT
59%
Loosely correlated
-0.34%
NTLA - EDIT
56%
Loosely correlated
+2.15%
More